Asset
FORODESINE
BioCryst Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00035022 | phase1_2 | completed | 2001-08-01 | — | BioCryst Pharmaceuticals | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas |
FDA applications (0)
This company has no applications containing this asset.